Abstract:A major use of gold compounds in the pharmaceutical industry is for antiarthritic agents. The disease itself is not understood and little is known about the way in which the drugs act, but detailed pictures of the distribution of gold in the body are available, and some of the relevant biochemistry is beginning to emerge.
“…1, which was drawn with OR TEPII (Johnson, 1971) at 15% probability ellipsoids. Berners-Price & Sadler, 1987;Parish & Cottrill, 1987). Et3PAuC1 , which is known to interact with DNA (Mirabelli, Sung, Zimmerman, Hill, Mong & Crooke, 1986), has a similar coordination geometry to that reported for the triphenylphosphine analogue PhaPAuC1 (Baenziger, Bennett & Soboroff, 1976 …”
“…1, which was drawn with OR TEPII (Johnson, 1971) at 15% probability ellipsoids. Berners-Price & Sadler, 1987;Parish & Cottrill, 1987). Et3PAuC1 , which is known to interact with DNA (Mirabelli, Sung, Zimmerman, Hill, Mong & Crooke, 1986), has a similar coordination geometry to that reported for the triphenylphosphine analogue PhaPAuC1 (Baenziger, Bennett & Soboroff, 1976 …”
“…Studies on gold complexes have mainly focused on antiarthritic properties [16][17][18][19][20][21], but growing interest is evident in antitumoral [22][23][24], antiparasitic [25] and antibacterial activities. In this last field, the compounds under investigation include a major collection of the type R 3 PAuL, in which the gold atom is coordinated to a phosphine ligand and L is an O- [26,27], N- [28,29], Cl- [30] or S- [29,[31][32][33][34][35] 2 ], Na 3 [Au(mna) 2 ] (H 2 mna 02-mercaptonicotinic acid) [13] and the cationic complexes [Au(L) 2 ](NO 3 ) 3 (L01-[2-(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea) [34].…”
Reaction of NaAuCl 4 ·H 2 O and thiodiglycol (1:3 molar ratio) with 3-(aryl)-2-sulfanylpropenoic acids, C NMR spectroscopy. The antimicrobial activities of the complexes against Escherichia coli, Staphylococcus aureus, Bacillus subtilis, Candida albicans, Pseudomonas aeruginosa and carbapenem-resistant P. aeruginosa were evaluated and compared to those of the equivalent silver(I) complexes. The comparison shows that the gold compounds generally show better activity than the silver analogues against S. aureus and B. subtilis, but low sensitivity against E. coli, P. aeruginosa and C. albicans, suggesting a different mode of antimicrobial action for equivalent silver and gold compounds.
“…The limitation of gold(III) compounds for use in drug development stems from the fact that gold(III) compounds tend to be thermally unstable and are reduced in physiological conditions. Gold(III) also tends to be toxic (Parish and Cottrill 1987). Nevertheless, a few gold(III) compounds have been reported to inhibit HIV.…”
Highly active antiretroviral therapy (HAART) has resulted in decreased mortality and morbidity from the acquired immune deficiency syndrome caused by the human immunodeficiency virus (HIV). Drug resistance and toxicity of HAART has led to the search for novel inhibitors of HIV infection. Gold-based compounds have shown promising activity against a wide range of clinical conditions and microorganism infections including HIV-1. A typical example is auranofin which resulted in an elevated CD4? T-cell count in an HIV patient being treated for psoriatic arthritis. In addition, reports exist on gold-based inhibitors of reverse transcriptase (RT), protease (PR) and viral entry of host cells. These and other characteristics of goldbased HIV drugs are reviewed here.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.